Pfizer Inc. (PFE)

Statement of Cash Flows

Annual Data | Quarterly Data

The cash flow statement provides information about a company's cash receipts and cash payments during an accounting period, showing how these cash flaws link the ending cash balance to the beginning balance shown on the company's statement of financial position.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Pfizer Inc., Consolidated Statement of Cash Flows

USD $ in millions

 
  12 months ended Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010 Dec 31, 2009
Net income before allocation to noncontrolling interests 22,072  14,598  10,051  8,289  8,644 
Depreciation and amortization 6,410  7,611  9,026  8,487  4,757 
Asset write-offs, impairments and related charges 1,368  1,299  1,198  3,486  305 
Gain on disposal of discontinued operations (10,446) (7,123) (1,688)
Gain associated with the transfer of certain product rights to an equity-method investment (459)
Deferred taxes from continuing operations 1,726  739  264  1,953  (9,582)
Deferred taxes from discontinued operations (23) 1,459  190 
Share-based compensation expense 523  481  419  405  349 
Acquisition-related in-process research and development charges 125  68 
(Gain) loss on disposals 15  (155) (670)
Benefit plan contributions (in excess of) less than expense 310  135  (1,775) (691) 545 
Other non-cash adjustments, net (324) (203) (189) (19) 199 
Accounts receivable 940  275  (66) (608) 252 
Inventories (538) (631) 1,084  2,917  1,631 
Other assets (822) 83  582  (896) (867)
Accounts payable 382  579 
Other liabilities (3,184) (3,438) 1,147  827  1,502 
Other tax accounts, net (170) 1,190  (18) (12,666) 9,454 
Changes in assets and liabilities, net of acquisitions and divestitures (3,392) (1,942) 2,729  (10,426) 11,972 
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities (4,307) 2,456  10,189  3,165  7,943 
Net cash provided by operating activities 17,765  17,054  20,240  11,454  16,587 
Purchases of property, plant and equipment (1,206) (1,327) (1,660) (1,513) (1,205)
Purchases of short-term investments (42,761) (24,018) (18,447) (11,082) (35,896)
Proceeds from redemptions and sales of short-term investments 41,127  25,302  14,176  5,699  43,522 
Net (purchases of) proceeds from redemptions and sales of short-term investments with original maturities of 90 days or less (4,277) 1,459  10,874  5,950  5,775 
Purchases of long-term investments (11,020) (11,145) (4,263) (4,128) (6,949)
Proceeds from redemptions and sales of long-term investments 7,555  4,990  2,147  4,737  6,504 
Acquisitions of businesses, net of cash acquired (15) (1,050) (3,282) (273) (43,123)
Acquisitions of intangible assets (259) (92) (222)
Proceeds from sale of business 11,850  2,376 
Other investing activities 231  185  501  118  100 
Net cash (used in) provided by investing activities (10,625) 6,154  2,200  (492) (31,272)
Proceeds from short-term borrowings 4,323  7,995  12,810  6,400  31,159 
Principal payments on short-term borrowings (4,234) (3) (3,826) (9,249) (34,969)
Net proceeds from (payments on) short-term borrowings with original maturities of 90 days or less 3,475  (8,204) (7,540) (1,297) 874 
Proceeds from issuances of long-term debt 6,618  24,023 
Principal payments on long-term debt (4,146) (1,513) (6,986) (6) (967)
Purchases of common stock (16,290) (8,228) (9,000) (1,000)
Cash dividends paid (6,580) (6,534) (6,234) (6,088) (5,548)
Proceeds from exercise of stock options 1,750  568  153 
Other financing activities 109  (80) 15  66  (91)
Net cash provided by (used in) financing activities (14,975) (15,999) (20,607) (11,174) 14,481 
Effect of exchange-rate changes on cash and cash equivalents (63) (2) (29) (31) 60 
Net increase (decrease) in cash and cash equivalents (7,898) 7,207  1,804  (243) (144)
Cash and cash equivalents, beginning 10,081  3,182  1,735  1,978  2,122 
Cash and cash equivalents, ending 2,183  10,389  3,539  1,735  1,978 
Source: Pfizer Inc., Annual Reports
Item Description The company
Net cash provided by operating activities The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. Pfizer Inc.'s net cash provided by operating activities declined from 2011 to 2012 but then slightly increased from 2012 to 2013.